胆管癌免疫治疗的研究进展
摘要
关键词
全文:
PDF (English)参考
管梅,白春梅.胆道系统肿瘤的药物治疗[J].协和医学杂志,2020
(03):325-333.
Eckel F, Schmid R M. Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials[J]. Chemotherapy, 2014(01):13-23.
Raval R R, Sharabi A B, Walker A J, et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer[J]. J Immunother Cancer, 2014(02):14.
Velcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer[J]. Am Soc Clin Oncol Educ Book, 2016(35):298-308.
Zheng L, Xue J, Jaffee E M, et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2013(06):1230-1240.
Oshikiri T, Miyamoto M, Shichinohe T, et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response[J]. J Surg Oncol, 2003(04):224-228.
Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer, 2013(10):2665-74.
Rimassa L, Personeni N, Aghemo A, et al. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine[J]. J Autoimmun, 2019(100):17-26.
Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells[J]. Mod Pathol, 2006(06):804-814.
Qi X W, Zhang F, Wu H, et al. Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis[J]. Sci Rep, 2015(05):8924.
Park S Y, Roh S J, Kim Y N, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact[J]. Oncol Rep, 2009(03):649-657.
Kaida M, Morita-Hoshi Y, Soeda A, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer[J]. J Immunother, 2011(01):92-99.
Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer[J]. Anticancer Res, 2005(05):3575-3579.
Koido S, Kan S, Yoshida K, et al. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy[J]. Anticancer Res, 2014(11):6353-6361.
Aruga A, Takeshita N, Kotera Y, et al. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer[J]. Clin Cancer Res, 2013(08):2224-2231.
Aruga A, Takeshita N, Kotera Y, et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer[J]. J Transl Med, 2014(12):61.
Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis[J]. Exp Ther Med, 2012(03):463-469.
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg, 2013(09):1609-17.
Lepisto A J, Moser A J, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors[J]. Cancer Ther, 20086(B): 955-964.
Lokman N A, Ween M P, Oehler M K, et al. The role of annexin A2 in tumorigenesis and cancer progression[J]. Cancer Microenviron, 2011(02):199-208.
Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker[J]. Int J Parasitol, 2010(10):1203-12.
Rucki A A, Foley K, Zhang P, et al. Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer[J]. Cancer Res, 2017(01):41-52.
Rosenberg S A, Restifo N P, Yang J C, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008(04):299-308.
Dudley M E, Gross C A, Langhan M M, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma[J]. Clin Cancer Res, 2010(24)6122-31.
Higuchi R, Yamamoto M, Hatori T, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case[J]. Surg Today, 2006(06):559-62.
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014(6184): 641-645.
Shimizu K, Kotera Y, Aruga A, et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2012(02):171-8.
买新佳,黄婧娟,陈洪雷.新兴免疫检查点VISTA在肿瘤与炎症中的作用[J].武汉大学学报(医学版),2020(02):275-279.
DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i6.5835
Refbacks
- 当前没有refback。
![Creative Commons License](http://licensebuttons.net/l/by-nc/4.0/88x31.png)
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。